Kaczkowski, Inc, 3924 W Markham St, Little Rock, AR 72205, US

InterveXion Therapeutics, LLC is a privately held clinical-stage biotech company based in Little Rock, Arkansas. They are dedicated to developing a comprehensive program of therapies for individuals with methamphetamine use disorder, including short and long-acting monoclonal antibodies and vaccines. Their lead product, devextinetug (IXT-m200), is currently in Phase 2 clinical development for the treatment of methamphetamine use disorder and overdose, with positive proof-of-concept data. InterveXion has received Fast Track designation from the FDA and has been fully funded by National Institute on Drug Abuse (NIDA) grants. With a team of experienced professionals, including their Chief Executive Officer, Chief Operating Officer, Chief Medical Officer, and Chief Scientific Officer, InterveXion is committed to addressing the significant health adversities caused by methamphetamine addiction. Their innovative approach aims to bind methamphetamine and prevent its entry into the central nervous system, offering potential breakthroughs in the treatment of methamphetamine use disorder. In addition to their current lead product, InterveXion is also working on follow-on programs, including a vaccine and long-acting monoclonal antibodies with reduced dose frequency.Generated from the website

L. Daniel Eaton

Sonitrol

Arkansas Artificial Eye Clinic

The Center for Alloplastic Facial Reconstruction